253 related articles for article (PubMed ID: 10898335)
1. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
4. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
5. Markers of bone turnover in bone metastases.
Fontana A; Delmas PD
Cancer; 2000 Jun; 88(12 Suppl):2952-60. PubMed ID: 10898339
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of bone and tumour markers in patients with malignant diseases.
Oremek GM; Weis A; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):987-90. PubMed ID: 12820336
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
9. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
10. The clinical use of bone resorption markers in patients with malignant bone disease.
Coleman RE
Cancer; 2002 May; 94(10):2521-33. PubMed ID: 12173317
[TBL] [Abstract][Full Text] [Related]
11. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
[TBL] [Abstract][Full Text] [Related]
12. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
14. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
[TBL] [Abstract][Full Text] [Related]
18. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
Ulrich U; Rhiem K; Schmolling J; Flaskamp C; Paffenholz I; Sälzer H; Bauknecht T; Schlebusch H
Arch Gynecol Obstet; 2001 Jan; 264(4):186-90. PubMed ID: 11205705
[TBL] [Abstract][Full Text] [Related]
19. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
